Please Share:: India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Visit http://indiaer.blogspot.com/ for complete details �� ��
Ipca Laboratories Ltd
Reco: BUY
CMP: Rs 299
Target Price: Rs 420
Solid performance, Upgrade estimates – Maintain Buy
· IPCA’s Q3FY12 results were in-line with expectations with a) Revenues at Rs6bn (up 30% YoY), b) EBITDA at Rs1.5bn (up 66% YoY) and c) APAT at Rs1bn (up 88% YoY)
· Revenue growth was led by strong growth in exports aided by INR dep. Domestic business continues to struggle but is expected to recover & grow by 13-15% in Q4’12E & FY13E
· Gross and EBITDA margins improved by 235bps and 550bps YoY to 61% and 25% respectively led by INR dep and strong uptake in institutional business which is expected to continue going forward
· On back of strong results and expected USFDA approval for Indore facility, we revise earnings upwards by 18%/ 7% for FY12/13E. Re-iterate Buy with a revised target of Rs420 (14xFY13 EPS)
No comments:
Post a Comment